Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

NCT05983276 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Decitabine
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Selinexor

Sponsor

Loyola University

Collaborators

[object Object]